Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of ABT-165 + FOLFIRI vs Bevacizumab + FOLFIRI in Previously Treated Metastatic Colorectal Cancer
2017-003669-87Phase 2Terminated
- Sponsor
- AbbVie Inc.
- Start
- Feb 2018
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dilpacimab in colorectal adenocarcinoma (mCRC) (2 arms), sponsored by AbbVie Inc. Primary endpoint: Progression-free survival. Started Feb 2018; status: terminated.
02
Drugs
dilpacimab
03
Conditions
colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2017-003669-87.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003669-87.